456 related articles for article (PubMed ID: 34361615)
21. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
22. Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology.
Di Sante G; Pagé J; Jiao X; Nawab O; Cristofanilli M; Skordalakes E; Pestell RG
Expert Rev Anticancer Ther; 2019 Jul; 19(7):569-587. PubMed ID: 31219365
[No Abstract] [Full Text] [Related]
23. Induced expression of p16(INK4a) inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes.
McConnell BB; Gregory FJ; Stott FJ; Hara E; Peters G
Mol Cell Biol; 1999 Mar; 19(3):1981-9. PubMed ID: 10022885
[TBL] [Abstract][Full Text] [Related]
24. [Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology].
Viallard JF; Lacombe F; Belloc F; Pellegrin JL; Reiffers J
Cancer Radiother; 2001 Apr; 5(2):109-29. PubMed ID: 11355576
[TBL] [Abstract][Full Text] [Related]
25. Cyclin-dependent kinase inhibition: an opportunity to target protein-protein interactions.
Klein MA
Adv Protein Chem Struct Biol; 2020; 121():115-141. PubMed ID: 32312419
[TBL] [Abstract][Full Text] [Related]
26. Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27Kip1 with cyclin A-Cdk2 and cyclin D2-Cdk4.
Blain SW; Montalvo E; Massagué J
J Biol Chem; 1997 Oct; 272(41):25863-72. PubMed ID: 9325318
[TBL] [Abstract][Full Text] [Related]
27. [Inhibitors of cyclin-dependent kinases (CDK) - a new group of medicines in therapy of advanced breast cancer].
Sarosiek T
Pol Merkur Lekarski; 2018 Jan; 44(259):5-9. PubMed ID: 29374415
[TBL] [Abstract][Full Text] [Related]
28. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2.
Prall OW; Sarcevic B; Musgrove EA; Watts CK; Sutherland RL
J Biol Chem; 1997 Apr; 272(16):10882-94. PubMed ID: 9099745
[TBL] [Abstract][Full Text] [Related]
29. Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein.
Wesierska-Gadek J; Schmid G
Expert Opin Investig Drugs; 2006 Jan; 15(1):23-38. PubMed ID: 16370931
[TBL] [Abstract][Full Text] [Related]
30. Cyclin D-CDK4/6 functions in cancer.
Gao X; Leone GW; Wang H
Adv Cancer Res; 2020; 148():147-169. PubMed ID: 32723562
[TBL] [Abstract][Full Text] [Related]
31. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
32. Mechanistic insights into avian reovirus p17-modulated suppression of cell cycle CDK-cyclin complexes and enhancement of p53 and cyclin H interaction.
Chiu HC; Huang WR; Liao TL; Chi PI; Nielsen BL; Liu JH; Liu HJ
J Biol Chem; 2018 Aug; 293(32):12542-12562. PubMed ID: 29907572
[TBL] [Abstract][Full Text] [Related]
33. Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors.
Parry D; Mahony D; Wills K; Lees E
Mol Cell Biol; 1999 Mar; 19(3):1775-83. PubMed ID: 10022865
[TBL] [Abstract][Full Text] [Related]
34. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies.
Bose P; Simmons GL; Grant S
Expert Opin Investig Drugs; 2013 Jun; 22(6):723-38. PubMed ID: 23647051
[TBL] [Abstract][Full Text] [Related]
35. P16Ink4a tumor suppressor function in lung cancer cells involves cyclin-dependent kinase 2 inhibition by Cip/Kip protein redistribution.
Grimison B; Langan TA; Sclafani RA
Cell Growth Differ; 2000 Oct; 11(10):507-15. PubMed ID: 11063124
[TBL] [Abstract][Full Text] [Related]
36. The history and future of targeting cyclin-dependent kinases in cancer therapy.
Asghar U; Witkiewicz AK; Turner NC; Knudsen ES
Nat Rev Drug Discov; 2015 Feb; 14(2):130-46. PubMed ID: 25633797
[TBL] [Abstract][Full Text] [Related]
37. Cyclin-dependent kinases in cancer: Role, regulation, and therapeutic targeting.
Gupta A; Dagar G; Chauhan R; Sadida HQ; Almarzooqi SK; Hashem S; Uddin S; Macha MA; Akil ASA; Pandita TK; Bhat AA; Singh M
Adv Protein Chem Struct Biol; 2023; 135():21-55. PubMed ID: 37061333
[TBL] [Abstract][Full Text] [Related]
38. Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation.
Watts CK; Brady A; Sarcevic B; deFazio A; Musgrove EA; Sutherland RL
Mol Endocrinol; 1995 Dec; 9(12):1804-13. PubMed ID: 8614416
[TBL] [Abstract][Full Text] [Related]
39. Keratin 19 regulates cell cycle pathway and sensitivity of breast cancer cells to CDK inhibitors.
Sharma P; Alsharif S; Bursch K; Parvathaneni S; Anastasakis DG; Chahine J; Fallatah A; Nicolas K; Sharma S; Hafner M; Kallakury B; Chung BM
Sci Rep; 2019 Oct; 9(1):14650. PubMed ID: 31601969
[TBL] [Abstract][Full Text] [Related]
40. Inhibitors of Cyclin-Dependent Kinase 1/2 for Anticancer Treatment.
Mou J; Chen D; Deng Y
Med Chem; 2020; 16(3):307-325. PubMed ID: 31241436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
